Hangzhou Biotest Biotech Co Ltd Capital Reinvestment Ratio
Hangzhou Biotest Biotech Co Ltd capital reinvestment ratio. Hangzhou Biotest Biotech Co Ltd (688767) has a Capital Reinvestment Ratio of 1.66x as of September 2025, meaning it reinvests 2% of its operating cash flow (CN¥28.39 Million) in capital expenditures (CN¥47.02 Million). See cash generation quality of Hangzhou Biotest Biotech Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Hangzhou Biotest Biotech Co Ltd (2017–2025)
Capital reinvestment ratio of Hangzhou Biotest Biotech Co Ltd from 2017 to 2025. This chart tracks Hangzhou Biotest Biotech Co Ltd's Capital Reinvestment Ratio across 9 annual periods. See 688767 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Hangzhou Biotest Biotech Co Ltd Capital Reinvestment Ratio by Year (2017–2025)
Hangzhou Biotest Biotech Co Ltd capital reinvestment ratio by year from 2017 to 2025. For the full cash flow conversion analysis, see Hangzhou Biotest Biotech Co Ltd cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.22x | CN¥106.47 Million | CN¥129.87 Million | ▼ -35.9% |
| 2024 | 1.90x | CN¥128.83 Million | CN¥245.05 Million | ▲ +342.9% |
| 2023 | 0.43x | CN¥131.38 Million | CN¥56.42 Million | ▲ +68.8% |
| 2022 | 0.25x | CN¥703.21 Million | CN¥178.92 Million | ▲ +15.4% |
| 2021 | 0.22x | CN¥908.12 Million | CN¥200.20 Million | ▲ +70.5% |
| 2020 | 0.13x | CN¥446.07 Million | CN¥57.68 Million | ▼ -91.6% |
| 2019 | 1.54x | CN¥25.67 Million | CN¥39.47 Million | ▲ +157.0% |
| 2018 | 0.60x | CN¥21.17 Million | CN¥12.67 Million | ▼ -83.9% |
| 2017 | 3.73x | CN¥7.07 Million | CN¥26.37 Million | — |